Mark Chen
Something unusual is happening in brain cancer research right now, and it’s not a new drug. It’s a diet. In January 2026, a Phase 2 clinical trial called Diet2Treat officially opened enrollment at several major US cancer centers, including UCSF Brain Tumor Center and Pacific Neuroscience Institute, with a goal of recruiting 170 newly diagnosed glioblastoma patients. The trial is testing whether a ketogenic diet, run alongside standard chemoradiation, can improve outcomes in one of the most lethal cancers we know. Median survival for glioblastoma multiforme is roughly 15 months. Five-year survival is under 10 percent. When you’re working with those numbers, even a dietary intervention that might shift tumor biology gets serious scientific attention.
I’ll be honest: I’ve watched keto-oncology go through a long hype cycle. The Warburg effect, the idea that cancer cells are glucose-dependent and might be starved by ketosis, has been a compelling hypothesis for decades. But compelling hypotheses are everywhere in cancer research. What’s different now is that Diet2Treat represents the most rigorous, well-resourced test of this idea in glioblastoma that we’ve seen. And it comes on the heels of real safety data, not just theory.
What the Phase 1 Data Actually Showed
Before you run a Phase 2 trial on cancer patients, you need to know the intervention isn’t going to hurt them. That’s what the precursor study did. Published in Nature Scientific Reports in July 2025, a Phase 1 trial tested a 16-week ketogenic diet at a 3:1 fat-to-protein-plus-carb ratio in GBM patients who were simultaneously undergoing chemoradiation. The finding was that the protocol was safe and feasible. That’s not a glamorous headline, but it matters enormously.
Chemoradiation is brutal. Patients are fatigued, nauseated, and struggling to eat enough. The assumption many clinicians had was that asking these patients to also follow a highly restrictive ketogenic diet would be unrealistic or would compromise their nutrition. The Phase 1 data pushed back on that assumption. Patients were able to maintain the diet, and no serious diet-related adverse events emerged.
What surprised me was how this changed the ethical calculus for the Phase 2 trial. The safety signal cleared the path. Now the question moves from “can patients do this?” to “does it help them?”
The Biological Rationale (and Where It Gets Complicated)
The core idea is worth unpacking because it sounds almost too clean. Glioblastoma cells, like many aggressive cancers, rely disproportionately on glucose metabolism for energy, a phenomenon called the Warburg effect. The hypothesis is that by pushing the body into ketosis, you reduce circulating blood glucose, potentially starving tumor cells of a preferred fuel source. Meanwhile, healthy brain cells, which are metabolically flexible, can shift to using ketones instead.
The theory is elegant. The reality is messier. Tumors are not simple. Glioblastoma is particularly heterogeneous, meaning different cells within the same tumor can have different metabolic profiles. Some research suggests certain GBM cells can adapt and use ketones or fatty acids as fuel. There’s also the question of whether dietary-induced ketosis produces blood glucose reductions deep enough and sustained enough to meaningfully affect tumor metabolism in humans, not just in cell cultures or mouse models.
The research here is genuinely mixed at the mechanistic level. What Diet2Treat is trying to do is bypass that uncertainty by asking the clinical question directly: does it change survival? That’s the right question to ask, and randomizing 170 patients is a serious attempt to answer it.
How the Trial Is Actually Structured
This isn’t a loosely defined lifestyle intervention. The design is specific, which matters for interpreting whatever results eventually come.
| Feature | Ketogenic Diet Group | Standard Diet Group |
|---|---|---|
| Randomization | 1:1 (half of 170 patients) | 1:1 (half of 170 patients) |
| Dietary intervention | Supervised KD for 18 weeks | Standard anti-cancer dietary guidance |
| Background treatment | Standard chemoradiation | Standard chemoradiation |
| Monitoring | Daily ketone + glucose tracking | Not specified |
| Dietitian involvement | Trained research dietitians | Standard care |
| Primary sites | UCSF, Pacific Neuroscience Institute, others | Same sites |
According to the UCSF Brain Tumor Center trial listing, patients are actively monitored for dietary adherence using daily ketone and glucose measurements. That’s a meaningful detail. Most nutrition trials have notoriously weak adherence monitoring. Daily biomarker tracking at least gives researchers a real picture of who was actually in ketosis and for how long, which will be critical for interpreting the data.
The Pacific Neuroscience Institute’s trial listing confirms enrollment began January 21, 2026, and the multi-site design increases the likelihood of hitting the 170-patient target within a reasonable timeline, which has historically been a bottleneck in keto-oncology research.
What This Means (and Doesn’t Mean) for Keto as a Cancer Tool
I want to be careful here, because this is where things can go sideways. Diet2Treat is studying a very specific population: newly diagnosed glioblastoma patients receiving chemoradiation. The results, whatever they are, will not tell us whether keto helps with breast cancer, prostate cancer, or any other malignancy. The metabolic profile of GBM makes it a particularly logical target for this hypothesis. Other cancers have different metabolic dependencies.
It also won’t tell us that people with cancer should self-prescribe ketogenic diets outside of supervised clinical settings. The Phase 1 trial worked because patients had trained dietitians, daily monitoring, and medical oversight throughout. Glioblastoma patients who adopt keto independently may or may not maintain therapeutic ketosis, may create nutritional deficits during an already physiologically stressful treatment period, and have no way of knowing whether the timing and composition of their diet matches what’s being tested.
The trial also won’t produce overall survival data for several years. Even if recruitment proceeds well, GBM survival endpoints take time to mature. We are likely looking at 2028 or 2029 before meaningful results are published. Patience is required.
Why This Trial Matters Beyond Glioblastoma
What strikes me about Diet2Treat is what it represents as a methodological moment. For years, keto-oncology has lived in a frustrating space: biologically plausible, championed by enthusiasts, underpowered in the evidence base. The trials that existed were mostly small, single-site, and lacking control groups. Clinicians had a hard time doing anything useful with that literature.
A 170-patient, multi-site, randomized controlled Phase 2 trial is a different category of evidence. If Diet2Treat shows a survival benefit, it will be the strongest signal yet that metabolic manipulation deserves a real place in oncology. If it shows no benefit, that’s also genuinely useful: it will help redirect research toward other strategies and spare future patients from an intervention that doesn’t move the needle.
Either outcome advances the science. That’s what good trials do.
Anyone newly diagnosed with glioblastoma or involved in their care should speak directly with their oncology team and ask whether they qualify for Diet2Treat enrollment. This is not a supplement or a hack. It’s a serious clinical investigation being run by serious institutions, and if you or someone you know is facing this diagnosis, participation in well-designed research is one of the most meaningful options available.
Sources
- UCSF Brain Tumor Center – Phase II Ketogenic Diet vs. Standard Diet in Glioblastoma (January 2026)
- Pacific Neuroscience Institute – Diet2Treat Trial Listing (January 21, 2026)
- UCSF Clinical Trials – Ketogenic Diet for Glioblastoma (Recruiting) (May 2026)
- Froedtert & Medical College of Wisconsin – Diet2Treat Overview (2026)
- Nature Scientific Reports – Phase 1 KD Safety Trial in GBM (July 1, 2025)
Photo: Ronit HaNegby via Pexels
This article is for general informational purposes only and does not constitute medical or dietary advice. Always consult a licensed healthcare provider or registered dietitian before making significant changes to your diet, especially if you have a medical condition.
